Imatinib Dr. Reddy’s

Imatinib, the active ingredient in Imatinib Dr. Reddy’s, is a tyrosine kinase inhibitor presented as an oral tablet for oral use. It is indicated for the treatment of chronic myeloid leukemia, Philadelphia chromosome‑positive acute lymphoblastic leukemia, gastrointestinal stromal tumor, and systemic mastocytosis in appropriate patients.

GNH USA supplies Imatinib Dr. Reddy’s as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies, and clinics across multiple regions worldwide. The company adheres to stringent quality standards and provides regulatory support for import and distribution.

Imatinib acts on abnormal tyrosine‑kinase signaling pathways in certain hematologic and solid tumors. - Chronic myeloid leukemia (CML): reduces leukemic cell proliferation and improves survival. - Philadelphia chromosome‑positive acute lymphoblastic leukemia (Ph+ ALL): targets the BCR‑ABL fusion protein to achieve remission. - Gastrointestinal stromal tumor (GIST): inhibits c‑KIT driven tumor growth. - Systemic mastocytosis: blocks KIT signaling to control disease activity.

Imatinib may cause a range of adverse reactions, varying in frequency and severity.

Common Side Effects: - Nausea and vomiting. - Peripheral edema. - Muscle cramps or weakness. - Fatigue or asthenia. - Diarrhea. - Skin rash or pruritus.

Serious or Rare Side Effects: - Neutropenia or severe leukopenia. - Hepatotoxicity with elevated transaminases. - Cardiac failure or reduced left‑ventricular ejection fraction. - Severe skin reactions such as Stevens‑Johnson syndrome. - Pulmonary hypertension. - Tumor lysis syndrome.

Patients receiving Imatinib should be monitored for several safety considerations. - Monitor blood counts: regular CBC to detect cytopenias. - Assess liver function: periodic LFTs for hepatotoxicity. - Evaluate cardiac status: baseline and periodic ECG for heart‑failure risk. - Avoid use in patients with known hypersensitivity to imatinib. - Pregnancy and lactation: use only if potential benefit justifies risk; data limited. - Store at ambient temperature: keep below 25 °C, in original container, protect from moisture and light.

Imatinib interacts with several medicines that can alter its effectiveness or safety.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase imatinib exposure. - Strong CYP3A4 inducers (e.g., rifampin, phenytoin): may reduce efficacy. - Antacids containing aluminum or magnesium: may decrease absorption. - QT‑prolonging agents: additive risk of arrhythmia.

Moderate Interactions (Monitor Closely): - Warfarin: imatinib may enhance anticoagulant effect; monitor INR. - Corticosteroids: may alter imatinib metabolism; adjust dose if needed. - Live vaccines: may be less effective; consider timing of administration.